[{"abstract": "Wall Street analysts are cutting their sales estimates for Exubera, which has been dogged by questions about its safety, cost and convenience.", "web_url": "https://www.nytimes.com/2007/04/10/business/10drug.html", "snippet": "Wall Street analysts are cutting their sales estimates for Exubera, which has been dogged by questions about its safety, cost and convenience.", "lead_paragraph": "Exubera, the first and so far only commercially available inhaled-insulin diabetes treatment, is on the verge of turning into an expensive failure for its maker, Pfizer. ", "print_section": "C", "print_page": "1", "source": "The New York Times", "multimedia": [{"rank": 0, "subtype": "thumbnail", "caption": null, "credit": null, "type": "image", "url": "images/2007/04/10/business/10drug.75.jpg", "height": 75, "width": 75, "subType": "thumbnail", "crop_name": "thumbStandard", "legacy": {"thumbnail": "images/2007/04/10/business/10drug.75.jpg", "thumbnailwidth": 75, "thumbnailheight": 75}}], "headline": {"main": "Pfizer Drug for Diabetes Is Lagging", "kicker": null, "content_kicker": null, "print_headline": "Pfizer Drug For Diabetes Is Lagging", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "organizations", "value": "Pfizer Inc", "rank": 1, "major": "N"}, {"name": "subject", "value": "Exubera (Drug)", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "subject", "value": "Sales", "rank": 4, "major": "N"}, {"name": "subject", "value": "Medicine and Health", "rank": 5, "major": "N"}, {"name": "subject", "value": "Diabetes", "rank": 6, "major": "N"}], "pub_date": "2007-04-10T04:00:00+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "byline": {"original": "By Alex Berenson", "person": [{"firstname": "Alex", "middlename": null, "lastname": "Berenson", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/251419c4-dce1-5b69-b68f-260005513c63", "word_count": 1063, "uri": "nyt://article/251419c4-dce1-5b69-b68f-260005513c63"}, {"abstract": "A consumer group has asked the F.D.A. to ban the long and unconventional ad, saying it gives a false impression.", "web_url": "https://www.nytimes.com/2007/04/10/business/media/10celebrex.web.html", "snippet": "A consumer group has asked the F.D.A. to ban the long and unconventional ad, saying it gives a false impression.", "lead_paragraph": "A new television advertisement for Pfizer\u2019s painkiller Celebrex that has attracted attention for both its length and innovative marketing approach is now also the target of criticism for its message.", "source": "The New York Times", "multimedia": [], "headline": {"main": "Celebrex Commercial Draws Criticism", "kicker": null, "content_kicker": null, "print_headline": "</hl1> <hl2 class=", "name": null, "seo": null, "sub": null}, "keywords": [{"name": "subject", "value": "Celebrex (Drug)", "rank": 1, "major": "N"}, {"name": "organizations", "value": "Pfizer Inc", "rank": 2, "major": "N"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "rank": 3, "major": "N"}, {"name": "subject", "value": "ADVERTISING AND MARKETING", "rank": 4, "major": "N"}], "pub_date": "2007-04-10T04:00:00+0000", "document_type": "article", "news_desk": "Business", "section_name": "Business Day", "subsection_name": "Media", "byline": {"original": "By Stephanie Saul", "person": [{"firstname": "Stephanie", "middlename": null, "lastname": "Saul", "qualifier": null, "title": null, "role": "reported", "organization": "", "rank": 1}], "organization": null}, "type_of_material": "News", "_id": "nyt://article/fb7510d6-dfa5-505a-ad6e-c827d76cf9d7", "word_count": 828, "uri": "nyt://article/fb7510d6-dfa5-505a-ad6e-c827d76cf9d7"}]